| TITLE |
DATE |
| Samsung and Biogen Idec Announce Joint Venture to Develop,
Manufacture and Market Biosimilars |
5-Dec-2011 |
| Biogen Idec to Present at the 2011 Deutsche Bank BioFEST |
30-Nov-2011 |
| Biogen Idec Reports Third Quarter 2011 Results |
28-Oct-2011 |
| Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases |
27-Oct-2011 |
| Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2b Trial at ECTRIMS/ACTRIMS |
26-Oct-2011 |
| Biogen Idec Announces Positive Top-Line Results from Second Phase 3
Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis |
26-Oct-2011 |
| Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple
Sclerosis (MS) Relapses and Disability Progression in Define Phase 3
Clinical Trial |
21-Oct-2011 |
| Biogen Idec and Elan Receive Notification of PDUFA Date Extension |
20-Oct-2011 |
| Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th
Joint Triennial Congress of ECTRIMS and ACTRIMS |
19-Oct-2011 |
| Data Presented at the 5th Joint Triennial
Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec's Novel Science
and Commitment to MS Patients |
12-Oct-2011 |
| Biogen Idec to Report Third Quarter 2011 Financial Results on October
28, 2011 |
11-Oct-2011 |
| More Than 1,000 Biogen Idec Employees across the Globe Help Patients,
Communities in First "Care Deeply Volunteer Day" |
30-Sep-2011 |
| Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations |
29-Sep-2011 |
| Biogen Idec to Present at the UBS Global Life Sciences Conference |
14-Sep-2011 |
| Biogen Idec to Present at the Morgan Stanley 2011 Global Healthcare
Unplugged Conference |
8-Sep-2011 |
| Biogen Idec Fully Acquires Biogen Dompé Joint Ventures |
6-Sep-2011 |
| Biogen Idec Announces Webcast of Hemophilia R&D Roundtable |
31-Aug-2011 |
| Biogen Idec to Present at the Stifel Nicolaus 2011 Healthcare
Conference |
30-Aug-2011 |
| Biogen Idec and Abbott Announce Positive Top-Line Results from the
First Registrational Trial for Daclizumab HYP in Relapsing-Remitting
Multiple Sclerosis |
9-Aug-2011 |
| Biogen Idec Strengthens MS ActiveSource(R)
for People with Multiple Sclerosis |
27-Jul-2011 |
| Biogen Idec Reports Second Quarter 2011 Results |
26-Jul-2011 |
| Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting
Recombinant Factor VIII Therapy at International Society on Thrombosis
and Haemostasis Meeting |
26-Jul-2011 |
| Biogen Idec Receives Conditional Approval in the European Union for
FAMPYRA(R) to Improve Walking in Adults with
Multiple Sclerosis |
25-Jul-2011 |
| Biogen Idec to Report Second Quarter 2011 Financial Results on July
26, 2011 |
7-Jul-2011 |
| Biogen Idec Researchers Identify Novel Approach for Promoting
Remyelination and Inhibiting Autoimmune Activation as Potential
Therapeutic Option for Treatment of Multiple Sclerosis |
3-Jul-2011 |
| European Commission Approves Inclusion of Anti-JC Virus Antibody
Status as a PML Risk Factor in TYSABRI Labeling |
22-Jun-2011 |
| CORRECTING and REPLACING Biogen Idec Receives Approval in the
European Union for AVONEX(R) PEN(TM) |
7-Jun-2011 |
| Biogen Idec Receives Approval in the European Union for AVONEX(R)
PEN(TM) |
7-Jun-2011 |
| CORRECTING and REPLACINGBiogen Idec Reports Positive Data
from AVONEX Dose Titration Study at 2011 Annual Meeting of the
Consortium of Multiple Sclerosis Centers |
6-Jun-2011 |
| Biogen Idec Reports Positive Data from AVONEX Dose Titraion Study at
2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers |
6-Jun-2011 |
| Biogen Idec to Present at the Goldman Sachs 32nd
Annual Global Healthcare Conference |
1-Jun-2011 |
| Biogen Idec to Present at the Jefferies 2011 Global Healthcare
Conference |
1-Jun-2011 |
| Biogen Idec 2011 Annual Shareholder Meeting Webcast |
26-May-2011 |
| 2,700 Students in Greater Boston and North Carolina to Benefit from
Biogen Idec Foundation Science Education Grants |
26-May-2011 |
| Biogen Idec Celebrates World MS Day |
25-May-2011 |
| Biogen Idec Launches Women in MS Educational Initiative |
24-May-2011 |
| European Medicines Agency's Committee for Medicinal Products for
Human Use Issues Positive Opinion on Marketing Authorisation Application
for FAMPYRA |
20-May-2011 |
| Biogen Idec Receives Approval for FAMPYRA in Australia to Improve
Walking Ability in Adult Patients with MS |
16-May-2011 |
| Biogen Idec and Swedish Orphan Biovitrum Receive Opinion from EMA on
Pediatric Plan for Long-Lasting Hemophilia B Therapy |
9-May-2011 |
| Biogen Idec to Present at the Bank of America Merrill Lynch 2011
Healthcare Conference |
4-May-2011 |
| Biogen Idec to Present at the Deutsche Bank 36th Annual Healthcare
Conference |
27-Apr-2011 |
| Biogen Idec Reports First Quarter 2011 Results |
21-Apr-2011 |
| FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis |
19-Apr-2011 |
| Biogen Idec Receives Positive Opinion from the CHMP and Authorisation
from Health Canada on AVONEX PEN |
19-Apr-2011 |
| CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody
Status as a Third Factor to Further Stratify Risk of PML |
18-Apr-2011 |
| CORRECTING and REPLACING Biogen Idec to Report First Quarter 2011
Financial Results on April 21, 2011 Before Market Open, Conference Call
at 7:00 am ET |
14-Apr-2011 |
| Biogen Idec's Ongoing Dedication to People Living with MS Showcased
in Data Presented at the 63rd Annual Meeting of
the American Academy of Neurology |
11-Apr-2011 |
| Biogen Idec Announces Positive Top-Line Results from the First Phase
3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple
Sclerosis |
11-Apr-2011 |
| CORRECTING and REPLACING Biogen Idec to Report First Quarter 2011
Financial Results on April 21, 2011 After Market Close, Conference Call
at 4:30 pm ET |
7-Apr-2011 |
| Biogen Idec to Report First Quarter 2011 Financial Results on April
21, 2011 |
6-Apr-2011 |
| Biogen Idec and Knopp Biosciences Announce Enrollment of the First
Patient in a Global Phase III Study of Dexpramipexole for ALS |
31-Mar-2011 |
| Biogen Idec to Present at the Cowen 31st
Annual Healthcare Conference |
3-Mar-2011 |
| Biogen Idec to Present at the Citi 2011 Global Healthcare Conference |
24-Feb-2011 |
| Biogen Idec to Present at the ISI Annual Conference |
9-Feb-2011 |
| CORRECTING and REPLACING Biogen Idec Reports Full Year and Fourth
Quarter 2010 Results |
1-Feb-2011 |
| Biogen Idec Reports Full Year and Fourth Quarter 2010 Results |
1-Feb-2011 |
| FDA Approves RITUXAN for First-Line Maintenance Use in Follicular Lymphoma |
31-Jan-2011 |
| Biogen Idec Receives Negative Opinion from the CHMP on FAMPYRA |
21-Jan-2011 |
| Biogen Idec to Report Fourth Quarter and Year End 2010 Financial
Results on February 1, 2011 |
14-Jan-2011 |
| Biogen Idec Provides Business Update at Investor Meeting |
11-Jan-2011 |
| Biogen Idec to Present at the 29th Annual
J.P. Morgan Healthcare Conference |
5-Jan-2011 |
| Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to
Head Corporate Development |
5-Jan-2011 |
| Biogen Idec and Elan Submit Applications to Update TYSABRI Labeling
That May Help Stratify Risk of PML with Anti-JC Virus Antibody Status |
22-Dec-2010 |
| Biogen Idec and Neurimmune Announce Agreement on Three
Neurodegenerative Disease Programs |
20-Dec-2010 |
| Amanda Freitag of Chopped and Iron Chef America Teams up with
Multiple Sclerosis Nutritionist to Create Nutrition Resource for People
with MS |
17-Dec-2010 |
 |
